MindWalk Holdings provides AI tools and laboratory services for drug discovery to pharmaceutical and biotech companies. It last closed at $0.91 on Nov 17, down 3.87% on the day. HYFT reports earnings on Mon, Dec 21, 2026.
From HYFT's SEC filings, latest 20-F for the period ending Jan 31, 2026 (filed Jul 23). Last 12 months adds up the four latest quarters. Figures are in CAD. Per share figures are left out because the US listing can represent a different number of shares.
HYFT · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 20% below its 20 day and 39% below its 50 day average. It is 48% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), near oversold. The nearest support is the Pivot S1 at $0.90, and the nearest resistance the Pivot at $0.91.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 10.1%/day
Key levels
$2.9952 week high+228.6%
$1.34200 day average+47.3%
$1.33100 day average+46.2%
$1.27Swing high (Oct 29)+39.6%
$1.2650 day average+38.5%
$1.0920 day average+19.8%
$0.92Pivot R1+1.1%
$0.9152 week low+0.0%
$0.91Pivot+0.0%
$0.91Last close
$0.90Pivot S1−1.1%
Indicators
RSI (14)
30.88
Weak, oversold below 30
Neutral
MACD
-0.09
Below its signal line
Bearish
Stochastic
14.8
Near the bottom of its range
Oversold
ADX (14)
15.6
No clear trend
Williams %R
-100.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-147.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−17.6%
Change over 10 sessions
Bearish
ATR (14)
$0.09
Typical daily range, 10.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 26.0%/day
Key levels
$2.9952 week high+228.6%
$1.34200 day average+47.3%
$1.33100 day average+46.2%
$1.27Swing high (Oct 29)+39.6%
$1.2650 day average+38.5%
$1.0920 day average+19.8%
$0.92Pivot R1+1.1%
$0.9152 week low+0.0%
$0.91Pivot+0.0%
$0.91Last close
$0.90Pivot S1−1.1%
Indicators
RSI (14)
33.17
Weak, oversold below 30
Neutral
MACD
-0.11
Below its signal line
Bearish
Stochastic
8.2
Near the bottom of its range
Oversold
ADX (14)
12.8
No clear trend
Williams %R
-100.0
Oversold below −80, overbought above −20
Oversold
CCI (20)
-221.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−30.8%
Change over 10 sessions
Bearish
ATR (14)
$0.24
Typical daily range, 26.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for HYFT
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how HYFT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow HYFT usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How HYFT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HYFT is in one of them and how their past HYFT trades turned out.
MindWalk Holdings is an AI company based in Austin, Texas that applies artificial intelligence and laboratory work to drug discovery. Its LensAI software and ReefIQ data layer help life sciences companies analyze biological data and connect it to AI models. Clients can access the platform through projects, software subscriptions and integrations, and the company also develops its own antibody and vaccine candidates. Its customers are mainly pharmaceutical and biotech companies, served directly and through Talem, a unit that offers partnerships.